title: Defining the Value of a Comparative Approach to Cancer Drug Development.
abstract: Comparative oncology as a tool in drug development requires a deeper examination of the value of the approach and examples of where this approach can satisfy unmet needs. This review seeks to demonstrate types of drug development questions that are best answered by the comparative oncology approach. We believe common perceived risks of the comparative approach relate to uncertainty of how regulatory bodies will prioritize or react to data generated from these unique studies conducted in diseased animals, and how these new data will affect ongoing human clinical trials. We contend that it is reasonable to consider these data as potentially informative and valuable to cancer drug development, but as supplementary to conventional preclinical studies and human clinical trials particularly as they relate to the identification of drug-associated adverse events. Clin Cancer Res; 22(9); 2133-8. ©2015 AACR.
authors.affiliation: Comparative Oncology Program, Center for Cancer Research, NCI, NIH, Bethesda, Maryland. amy.leblanc@nih.gov.
authors.forename: Amy K
authors.initials: AK
authors.lastname: LeBlanc
authors.affiliation: Comparative Oncology Program, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
authors.forename: Christina N
authors.initials: CN
authors.lastname: Mazcko
authors.affiliation: Comparative Oncology Program, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
authors.forename: Chand
authors.initials: C
authors.lastname: Khanna
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D055808:Drug Discovery / Q000379:methods; D006801:Humans; D008495:Medical Oncology / Q000379:methods; D009369:Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents